RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RNAZ

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/11/14	06 : 34	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/11/12	21 : 00	GlobeNewswire Inc.	TransCode Therapeutics Open Letter to Shareholders	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/11/07	06 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/11/07	06 : 01	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/11/07	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/11/05	21 : 00	GlobeNewswire Inc.	TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/10/29	05 : 02	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/10/23	20 : 00	GlobeNewswire Inc.	TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/10/16	06 : 23	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/10/10	20 : 00	GlobeNewswire Inc.	TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/09/28	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/09/17	20 : 00	GlobeNewswire Inc.	TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/09/10	20 : 00	GlobeNewswire Inc.	TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/09/05	20 : 00	GlobeNewswire Inc.	TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/08/28	19 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/08/17	06 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/08/15	20 : 00	GlobeNewswire Inc.	TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/08/15	05 : 45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/07/27	05 : 05	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/07/25	05 : 05	GlobeNewswire Inc.	TransCode Therapeutics, Inc. Announces Closing of Public Offering	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/07/24	22 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/07/24	21 : 18	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/07/23	11 : 30	GlobeNewswire Inc.	TransCode Therapeutics, Inc. Announces Pricing of Public Offering	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/07/23	05 : 10	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/07/23	05 : 07	GlobeNewswire Inc.	TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/19	05 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/19	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/14	21 : 00	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/14	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RNAZ	TransCode Therapeutics Inc
2024/06/10	21 : 45	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:RNAZ	TransCode Therapeutics Inc